News & Events
Disc Medicine to Present at Citi's 15th Annual BioPharma Virtual Conference
Cambridge, Mass. – September 8, 2020 – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will present at Citi’s 15th Annual BioPharma Virtual Conference today, Tuesday, September 8, 2020 at 2:20pm ET.
About Disc Medicine
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.
Media Contact:
Arleen Goldenberg
Verge Scientific Communications
202.930.4762
More News
Disc Medicine to Present at Citi's…
Cambridge, Mass. – September 8, 2020 – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates …
read more
Disc Medicine Expands Leadership T…
Jonathan Yu Named Senior Vice President of Corporate Strategy
William Savage, MD, PhD Appointed Vice President of Clinical Development
John Quisel, JD, PhD Joins Disc Me…
Cambridge, Mass. – January 28, 2020 – Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red…
read more
Disc Medicine Completes $50 Millio…
Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic dise…
read more
Disc Medicine Expands Pipeline Foc…
Enters into exclusive agreement with AbbVie for series of Hemojuvelin Antagonist Monoclonal Antibodies Cambridge, Mass. – October 29, 2019 – Disc Medicin…
read more
Introducing Disc Medicine, a New H…
Introducing Disc Medicine – we are a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell productions (eryt…
read more